Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NBRVNASDAQ:NERVNASDAQ:NXTCNASDAQ:RMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ANERVMinerva Neurosciences$1.76-1.4%$1.68$1.15▼$3.50$12.27M-0.3722,850 shs2,258 shsNXTCNextCure$0.45$0.47$0.22▼$7.25$12.62M1.07126,305 shs47,664 shsRMTIRockwell Medical$0.82+3.8%$1.01$0.78▼$5.15$28.09M1.61421,494 shs44,884 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%NERVMinerva Neurosciences0.00%-0.84%+15.14%+4.71%-44.20%NXTCNextCure0.00%-4.26%-7.08%-6.31%-71.70%RMTIRockwell Medical0.00%-11.00%-18.86%-29.90%-54.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences4.1226 of 5 stars3.04.00.04.62.20.01.3NXTCNextCure4.37 of 5 stars3.53.00.04.32.01.71.3RMTIRockwell Medical4.1723 of 5 stars3.73.00.04.11.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNBRVNabriva Therapeutics 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00184.90% UpsideNXTCNextCure 3.00Buy$3.50677.78% UpsideRMTIRockwell Medical 3.33Buy$4.00386.62% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00NERVMinerva NeurosciencesN/AN/A$0.21 per share8.52($3.67) per shareN/ANXTCNextCureN/AN/AN/AN/A$2.34 per shareN/ARMTIRockwell Medical$101.49M0.28$0.13 per share6.27$1.01 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ANERVMinerva Neurosciences$1.44M$0.822.14N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)NXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)RMTIRockwell Medical-$480K-$0.02N/AN/AN/A-0.27%-0.90%-0.47%8/6/2025 (Estimated)Latest NBRV, NERV, NXTC, and RMTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/12/2025Q1 2025RMTIRockwell Medical-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNBRVNabriva TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ARMTIRockwell MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNBRVNabriva Therapeutics0.120.850.52NERVMinerva NeurosciencesN/A9.219.21NXTCNextCureN/A10.2610.26RMTIRockwell Medical0.302.952.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNBRVNabriva Therapeutics0.27%NERVMinerva Neurosciences34.56%NXTCNextCure42.65%RMTIRockwell Medical23.31%Insider OwnershipCompanyInsider OwnershipNBRVNabriva Therapeutics1.63%NERVMinerva Neurosciences8.60%NXTCNextCure13.30%RMTIRockwell Medical1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableNXTCNextCure9028.05 million24.32 millionOptionableRMTIRockwell Medical30034.17 million33.53 millionOptionableNBRV, NERV, NXTC, and RMTI HeadlinesRecent News About These CompaniesRockwell Medical IncJune 24, 2025 | money.usnews.comBuy Rating for Rockwell Medical Amid Growth Potential and Market PositioningMay 19, 2025 | tipranks.comEarnings call transcript: Rockwell Medical Q1 2025 beats EPS forecast, stock jumpsMay 13, 2025 | uk.investing.comRockwell Medical, Inc. (NASDAQ:RMTI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comQ1 2025 Rockwell Medical Inc Earnings CallMay 13, 2025 | finance.yahoo.comRockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...May 13, 2025 | gurufocus.comQ1 2025 Rockwell Medical Inc Earnings Call TranscriptMay 12, 2025 | gurufocus.comRockwell Medical’s Earnings Call: Navigating TransitionMay 12, 2025 | tipranks.comRockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comRockwell Medical Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comRockwell Medical (RMTI) Q1 Revenue Exceeds Expectations Despite Sales DipMay 12, 2025 | gurufocus.comRockwell Medical Announces First Quarter 2025 Results | RMTI Stock NewsMay 12, 2025 | gurufocus.comRockwell Medical Inc Q1 2025 Earnings: EPS of -$0.05 Meets Estimates, Revenue of $18. ...May 12, 2025 | gurufocus.comRockwell Medical, Inc. (NASDAQ:RMTI) Major Shareholder Larson Family Inve Irrevocable Buys 57,000 SharesApril 16, 2025 | insidertrades.comRockwell Medical Investment Trust buys shares worth $94,017April 15, 2025 | investing.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025April 14, 2025 | gurufocus.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025 | RMTI Stock NewsApril 14, 2025 | gurufocus.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025April 14, 2025 | businesswire.comRockwell Medical stock target cut to $3 at H.C. WainwrightMarch 26, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, NERV, NXTC, and RMTI Company DescriptionsNabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Minerva Neurosciences NASDAQ:NERV$1.76 -0.03 (-1.40%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.NextCure NASDAQ:NXTC$0.45 0.00 (0.00%) As of 11:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Rockwell Medical NASDAQ:RMTI$0.82 +0.03 (+3.77%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
